Passage Bio Inc (PASG) Stock Price, Quote & News

Company Profile

Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company develops PBML04 for the treatment of metach...

Industry: Biotechnology

Sector: Healthcare

Phone: 267 866 0311

Website: www.passagebio.com

Address:

One Commerce Square, 2005 Market Street 39th Floor, Philadelphia, United States

LionEdge Jan. 31 at 2:19 PM

$PASG Data shows that a growing number of institutions are reporting positions in PASG, and certain large holders (like Lynx1 Capital) have meaningful stakes. That can signal confidence from professional investors.

0 · Reply

LionEdge Jan. 31 at 2:18 PM

$PASG

0 · Reply

juliano777 Jan. 23 at 2:58 PM

$PASG Why doesn't the CEO own any shares?

0 · Reply

juliano777 Jan. 22 at 3:35 PM

$PASG It's time to buy... 13,87$

2 · Reply

OfficialStocktwitsUser Jan. 16 at 5:57 AM

$PASG RSI: 59.32, MACD: 1.7950 Vol: 3.62, MA20: 13.37, MA50: 10.49 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

Mart7810 Jan. 14 at 2:10 AM

$PASG thx for the run! Maybe I'll buy back

0 · Reply

McLarkin Jan. 13 at 9:03 PM

$PASG feels like nearer fair value - all things considered.... exciting space

0 · Reply

semserus Jan. 13 at 7:29 PM

$PASG Despite the current "sell-off," analysts remain largely bullish on the company’s long-term prospects: Analyst Consensus: The stock maintains a Strong Buy rating from most analysts, with an average price target of $34.50. Cash Runway: Passage Bio recently updated its corporate presentation, noting that its current cash reserves should fund operations through the first quarter of 2027.

0 · Reply

semserus Jan. 13 at 7:21 PM

$PASG Reason the Price is Dropping ... As of January 13, 2026, the stock is trading around $15.66, down about 12% today. This follows a period of extreme volatility: Overbought Conditions: The stock surged over 83% in the two weeks leading up to January 8. Technical indicators like the RSI (Relative Strength Index) showed the stock was heavily overbought, making a "correction" or price drop likely. Profit-Taking: After approaching its 52-week high of $20.00, investors likely began selling to lock in gains, leading to the sharp 9.8% drop on Monday and further declines today.

0 · Reply

semserus Jan. 13 at 7:20 PM

$PASG Recent Insider Activity CEO Transaction: On January 8, 2026, CEO William Chou sold 4,076 shares at an average price of $18.44, totaling approximately $75,161. Mandated Sale: This was not a discretionary "dump" of the stock; it was a mandated sale to cover tax withholding obligations related to the vesting of Restricted Stock Units (RSUs). Remaining Stake: Following the sale, Chou still holds 6,524 shares, and he has another 10,000 RSUs scheduled to vest in January 2027.

0 · Reply

Passage Bio Reports Third Quarter 2025 Financial Results and Provides Recent Business Highlights

Nov 5, 2025, 7:00 AM EST - 3 months ago

Passage Bio to Present at Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Oct 14, 2025, 7:00 AM EDT - 4 months ago

Passage Bio to Participate in Chardan's 9th Annual Genetic Medicines Conference

Aug 28, 2025, 7:00 AM EDT - 5 months ago

Passage Bio to Participate in H.C. Wainwright 27th Annual Global Investment Conference

Aug 12, 2025, 7:00 AM EDT - 6 months ago

Passage Bio Reports Second Quarter 2025 Financial Results and Provides Recent Business Highlights

Jul 10, 2025, 7:00 AM EDT - 7 months ago

Passage Bio Announces 1-for-20 Reverse Stock Split

Jun 23, 2025, 7:00 AM EDT - 8 months ago

Passage Bio Reports Updated Interim Data from upliFT-D Study and Provides Program Update

May 13, 2025, 7:00 AM EDT - 9 months ago

Passage Bio Reports First Quarter 2025 Financial Results and Provides Recent Business Highlights

Mar 4, 2025, 7:00 AM EST - 1 year ago

Passage Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Recent Business Highlights

Feb 26, 2025, 7:00 AM EST - 1 year ago

Passage Bio to Participate in Upcoming Investor Conferences

Jan 10, 2025, 7:00 AM EST - 1 year ago

Passage Bio Announces Interim Data from upliFT-D Study in FTD-GRN and Provides Business Updates

Nov 6, 2024, 7:00 AM EST - 1 year ago

Passage Bio to Present at Guggenheim Securities Healthcare Innovation Conference

Oct 24, 2024, 7:00 AM EDT - 1 year ago

Passage Bio Presents Preclinical and Interim Clinical Data for PBFT02 in FTD-GRN at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual Conference

Sep 23, 2024, 7:00 AM EDT - 1 year ago

Passage Bio to Present at Chardan's 8th Annual Genetic Medicines Conference

Sep 10, 2024, 7:52 AM EDT - 1 year ago

Passage Bio Welcomes Tom Kassberg to Board of Directors

Aug 30, 2024, 7:00 AM EDT - 1 year ago

Passage Bio to Present at H.C. Wainwright 26th Annual Global Investment Conference

Aug 8, 2024, 7:00 AM EDT - 1 year ago

Passage Bio Reports Second Quarter 2024 Financial Results and Provides Recent Business Highlights

Aug 1, 2024, 7:00 AM EDT - 1 year ago

Passage Bio Out-licenses Three Pediatric Gene Therapy Programs to GEMMA Biotherapeutics and Enters New Research Collaboration

Jul 16, 2024, 7:00 AM EDT - 1 year ago

Passage Bio Announces Positive Feedback from FDA on Expansion of upliFT-D Trial of PBFT02 to Include FTD-C9orf72 Patients

Jun 5, 2024, 7:30 AM EDT - 1 year ago

Passage Bio to Present at Goldman Sachs 45th Annual Global Healthcare Conference

May 21, 2024, 8:00 AM EDT - 1 year ago

Passage Bio Announces Recipient of Third Annual Tachi Yamada Scholarship Award

May 14, 2024, 7:00 AM EDT - 1 year ago

Passage Bio Reports First Quarter 2024 Financial Results and Provides Recent Business Highlights

Apr 22, 2024, 7:00 AM EDT - 1 year ago

Passage Bio to Present at Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit

Mar 4, 2024, 7:00 AM EST - 2 years ago

Passage Bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Recent Business Highlights

Feb 27, 2024, 7:00 AM EST - 2 years ago

Passage Bio to Participate in Upcoming Investor Conferences

Jan 31, 2024, 7:30 AM EST - 2 years ago

Passage Bio to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Dec 20, 2023, 7:00 AM EST - 2 years ago

Passage Bio Announces Promising Initial Data From Phase 1/2 Clinical Trial of PBFT02 in FTD-GRN and Updated Strategic Priorities

Nov 17, 2023, 4:30 PM EST - 2 years ago

Passage Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

Nov 13, 2023, 7:00 AM EST - 2 years ago

Passage Bio Reports Third Quarter 2023 Financial Results and Provides Recent Business Highlights

Oct 30, 2023, 7:00 AM EDT - 2 years ago

Passage Bio to Present at Guggenheim's 5th Annual Inflammation, Neurology & Immunology Conference

Oct 20, 2023, 4:30 PM EDT - 2 years ago

Passage Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sep 25, 2023, 7:00 AM EDT - 2 years ago

Passage Bio to Present at Chardan's 7th Annual Genetic Medicines Conference

Aug 7, 2023, 7:15 AM EDT - 2 years ago

Passage Bio Reports Second Quarter 2023 Financial Results and Provides Recent Business Highlights

Aug 7, 2023, 7:00 AM EDT - 2 years ago

Passage Bio Announces Promising Interim Clinical Data from First Eight Patients with GM1 Gangliosidosis in Imagine-1 Study

Jul 31, 2023, 7:00 AM EDT - 2 years ago

Passage Bio Welcomes Dolan Sondhi, Ph.D. to Board Of Directors

Jun 5, 2023, 7:00 AM EDT - 2 years ago

Passage Bio to Present at Goldman Sachs 44th Annual Global Healthcare Conference

May 11, 2023, 7:00 AM EDT - 2 years ago

Passage Bio Reports First Quarter 2023 Financial Results and Provides Recent Business Highlights

Apr 21, 2023, 4:01 PM EDT - 3 years ago

Passage Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Apr 17, 2023, 7:00 AM EDT - 3 years ago

Passage Bio to Present at Chardan's 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit

Mar 27, 2023, 7:00 AM EDT - 3 years ago

Passage Bio to Present at Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Days

Mar 6, 2023, 1:07 PM EST - 3 years ago

Passage Bio, Inc. (PASG) Q4 2022 Earnings Call Transcript

Mar 6, 2023, 7:00 AM EST - 3 years ago

Passage Bio Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Recent Business Highlights

Feb 28, 2023, 11:39 PM EST - 3 years ago

Passage Bio Undervalued On Price, Long-Term Gene Therapy Prospects

Feb 28, 2023, 7:00 AM EST - 3 years ago

Passage Bio to Present at Cowen 43rd Annual Health Care Conference

Feb 27, 2023, 7:00 AM EST - 3 years ago

Passage Bio to Report Fourth Quarter and Full-Year 2022 Financial Results on March 6, 2023

Feb 24, 2023, 7:00 AM EST - 3 years ago

Passage Bio Presents Additional Interim Data from Imagine-1 Study for GM1 Gangliosidosis at 19th Annual WORLDSymposium™ 2023

Feb 15, 2023, 7:00 AM EST - 3 years ago

Passage Bio to Present Updated Interim Data from Imagine-1 Study for GM1 Gangliosidosis at 19th Annual WORLDSymposium™ 2023

Dec 14, 2022, 7:00 AM EST - 3 years ago

Passage Bio Announces Positive Interim Clinical Data from First Six Patients with GM1 Gangliosidosis in Imagine-1 Study

Nov 10, 2022, 10:26 AM EST - 3 years ago

Passage Bio, Inc. (PASG) Q3 2022 Earnings Call Transcript

Nov 10, 2022, 7:00 AM EST - 3 years ago

Passage Bio Reports Third Quarter 2022 Financial Results and Provides Business Updates

LionEdge Jan. 31 at 2:19 PM

0 · Reply

LionEdge Jan. 31 at 2:18 PM

$PASG

0 · Reply

juliano777 Jan. 23 at 2:58 PM

$PASG Why doesn't the CEO own any shares?

0 · Reply

juliano777 Jan. 22 at 3:35 PM

$PASG It's time to buy... 13,87$

2 · Reply

OfficialStocktwitsUser Jan. 16 at 5:57 AM

0 · Reply

Mart7810 Jan. 14 at 2:10 AM

$PASG thx for the run! Maybe I'll buy back

0 · Reply

McLarkin Jan. 13 at 9:03 PM

$PASG feels like nearer fair value - all things considered.... exciting space

0 · Reply

semserus Jan. 13 at 7:29 PM

0 · Reply

semserus Jan. 13 at 7:21 PM

0 · Reply

semserus Jan. 13 at 7:20 PM

0 · Reply

freddie04 Jan. 13 at 4:23 PM

$PASG lol….7 days of Chardan selling into fools !!

0 · Reply

semserus Jan. 12 at 5:39 PM

$PASG 07:45 AM EST, 11/12/2025 (MT Newswires) -- Passage Bio (PASG) has an average rating of buy and mean price target of $32.50, according to analysts polled by FactSet.

0 · Reply

blankstocker Jan. 12 at 2:08 PM

$PASG Dug around just a little and the only thing I see is that there were a lot of institutions filing in Nov that they had bought small amounts of shares in September. Clinical trials page had been updated to add an Australia site. Other than that, I’m not seeing a lot of new information anywhere. 🤔

0 · Reply

Trendrebel Jan. 12 at 1:44 PM

$PASG Well, I certainly did not expect this one of My stock to double first. No news, totally radio silence from company. But ok, I will take that...

0 · Reply

blankstocker Jan. 9 at 6:49 PM

$PASG one of the stocks in my portfolio I wasn’t paying much attention to. Guess I should’ve been paying closer attention and added a bit when I had the chance. 🤔

1 · Reply

BDE_Worldwide Jan. 9 at 5:22 PM

$PASG let runners run..

0 · Reply

BDE_Worldwide Jan. 8 at 5:37 PM

$PASG little rinse, shake 🫨 Now we roll…… 🚀

0 · Reply

stu4 Jan. 7 at 5:44 PM

$PASG As Chardan…has completed its mission !!! Sold into you fools for 4 days ….and GONEEEEE

2 · Reply

RocketLynx Jan. 7 at 2:39 PM

$PASG The pre-cancer angle is the real alpha: advanced adenomas are harder than “already-cancer,” and they’ve cited 81–82% sensitivity for that lane while keeping CRC performance in the 90s (92/90 pooled, plus 94/97 in one interim set and 97/97 in another)

0 · Reply

stockmoe12 Jan. 7 at 3:33 AM

$PASG

0 · Reply

stockmoe12 Jan. 7 at 3:33 AM

$PASG without hype … its moving so lets go to $100

0 · Reply

BDE_Worldwide Jan. 7 at 2:45 AM

$PASG surprised no one is posting/hyping this one.. 🤔

1 · Reply

Market Cap	36.56M
Revenue (ttm)	0.00
Net Income (ttm)	-64.77M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	37,008
Avg Vol	64,078
Day's Range	N/A - N/A
Shares Out	3.18M
Stochastic %K	47%
Beta	1.76
Analysts	Strong Sell
Price Target	$39.60